Biosimilars

Pharmacists should continue to monitor payer policy changes and reimbursement rates and improve understanding of electronic order entry.

Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.

Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.

As patents expire, the development of biosimilars may increase, opening up new opportunities to compare efficacies of these drugs.

Gregory also discussed the differences between specialty pharmacy distribution and physician’s office distribution, and the benefits of each for patients.

Biosimilars are also expanding rapidly, offering new opportunities for payers, patients, and providers.

Pharmacists will play a growing role in the use of biosimilars and guiding patients through the switching process.

Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.

Balancing clinicians’ priorities with the needs of patients and their families is crucial to ensure access and adherence to medications.

The willingness of biology labs to evolve has been essential to the incredible rise of biologic drugs.

Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, discussed the growing biosimilars landscape .

Choosing the best biosimilar based on reimbursement can be challenging.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Annual Asembia summit features insights from key opinion leaders, networking events, and continuing education sessions for pharmacists, pharmacy staff and stakeholders.

The FDA’s temporary Guidance for 503A compounding of shortage drugs was meant to be temporary and withdrawn once COVID-19 ended.

Individuals who are rituximab-naïve remained stable after 2 years of follow-up, the analysis shows.

Part 1 of this 2-part series examines USP <797> and <795> revisions for sterile and nonsterile compounding, veterinary compounding, FDA inspections of 503A pharmacies, and the interstate distribution of compounded prescriptions post Wellness Pharmacy v. FDA.

This method has proven economically appealing, but further confirmation of these findings is needed, according to investigators.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

Educating patients, providers improves acceptance, trust as number of approvals, indications grows

The treatment shows an acceptable toxicity profile and no new adverse events, according to results of analysis.

Pharmacists are the best resource at cancer center practices to ensure patients with cancer do not need to make the choice to stop or delay therapy due to financial reasons.

These alternatives to expensive biologic drugs can provide access to lifesaving treatments to more patients and cut costs for health systems.

A patient’s neurological symptoms diminished when he discontinued a biosimilar and started various new treatments.

The company is also launching Rezvoglar, a biosimilar to Lantus injection, for $92 per 5-pack of KwikPens.

The FDA has created an online, searchable database that contains information about biological products, including biosimilar and interchangeable ones.

A specialty pharmacy can effectively dispense, monitor, and follow-up with transplant patients who are maintained on the standard triple-drug immunosuppression regimen.

By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in reduced bone loss.

Biosimilars, staffing issues, and mail-order companies are key trends to watch.

Availability of TNF-alpha inhibitor biosimilars in Southern European markets led to lowered costs within the drug class, even after an increased consumption volume for these therapies.